Risk factors for thrombosis and recommendations for thromboprophylaxis78
Risk factors . | ||
---|---|---|
Treatment-related . | Patient-specific . | Myeloma-specific . |
IMiDs | Age | Active uncontrolled disease |
High-dose dexamethasone | Previous VTE | Hyperviscosity |
Erythropoietin | Infection | |
Anthracyclines | Surgical procedures | |
Multiagent chemotherapy | Cardiovascular comorbidities | |
Immobilization | ||
Inherited thrombophilia | ||
Central venous catheter |
Risk factors . | ||
---|---|---|
Treatment-related . | Patient-specific . | Myeloma-specific . |
IMiDs | Age | Active uncontrolled disease |
High-dose dexamethasone | Previous VTE | Hyperviscosity |
Erythropoietin | Infection | |
Anthracyclines | Surgical procedures | |
Multiagent chemotherapy | Cardiovascular comorbidities | |
Immobilization | ||
Inherited thrombophilia | ||
Central venous catheter |
Recommendations for thromboprophylaxis . | ||
---|---|---|
Risk factor . | Number of risk factors . | Therapy . |
Treatment-specific | ≥1 | LMWH or warfarin |
Patient-specific | 1 | ASA |
Myeloma-specific | 1 | ASA |
Patient- or myeloma-specific | ≥2 | LMWH or warfarin |
Recommendations for thromboprophylaxis . | ||
---|---|---|
Risk factor . | Number of risk factors . | Therapy . |
Treatment-specific | ≥1 | LMWH or warfarin |
Patient-specific | 1 | ASA |
Myeloma-specific | 1 | ASA |
Patient- or myeloma-specific | ≥2 | LMWH or warfarin |